4//SEC Filing
Lucchese Paul R 4
Accession 0001178913-10-000277
CIK 0000793279other
Filed
Feb 1, 7:00 PM ET
Accepted
Feb 2, 5:27 PM ET
Size
13.6 KB
Accession
0001178913-10-000277
Insider Transaction Report
Form 4
Lucchese Paul R
SVP and General Counsel
Transactions
- Disposition to Issuer
Stock Appreciation Rights (right to buy)
2010-01-05−15,000→ 0 totalExercise: $14.22Exp: 2016-07-17→ Common Stock, $0.01 par value per share (15,000 underlying) - Disposition to Issuer
Stock Appreciation Rights (right to buy)
2010-01-05−25,002→ 0 totalExercise: $0.41Exp: 2019-01-19→ Common Stock, $0.01 par value per share (25,002 underlying) - Disposition to Issuer
Stock Appreciation Rights (right to buy)
2010-01-05−60,000→ 0 totalExercise: $4.29Exp: 2018-01-25→ Common Stock, $0.01 par value per share (60,000 underlying) - Disposition to Issuer
Stock Appreciation Rights (right to buy)
2010-01-05−30,000→ 0 totalExercise: $11.53Exp: 2017-04-03→ Common Stock, $0.01 par value per share (30,000 underlying)
Footnotes (4)
- [F1]The stock-settled stock appreciation rights, which were exercisable in two equal installments beginning on January 19, 2010, were vested in full and assumed by Syneron Medical Ltd. ("Syneron") pursuant to a merger agreement between the Issuer and Syneron and replaced with stock-settled stock appreciation rights to purchase 7,278 ordinary shares of Syneron at an exercise price of $1.41 per share.
- [F2]The stock-settled stock appreciation rights, which were exercisable in four equal installments beginning on January 25, 2009, were vested in full and assumed by Syneron as a result of the merger and replaced with stock-settled stock appreciation rights to purchase 17,466 ordinary shares of Syneron at an exercise price of $14.74 per share.
- [F3]The stock-settled stock appreciation rights, which were exercisable in four equal installments beginning on April 3, 2008, were vested in full and assumed by Syneron as a result of the merger and replaced with stock-settled stock appreciation rights to purchase 8,733 ordinary shares of Syneron at an exercise price of $39.61 per share.
- [F4]The stock-settled stock appreciation rights, which were exercisable in four equal installments beginning on July 17, 2007, were vested in full and assumed by Syneron as a result of the merger and replaced with stock-settled stock appreciation rights to purchase 4,366 ordinary shares of Syneron at an exercise price of $48.85 per share.
Documents
Issuer
CANDELA CORP /DE/
CIK 0000793279
Entity typeother
Related Parties
1- filerCIK 0001369196
Filing Metadata
- Form type
- 4
- Filed
- Feb 1, 7:00 PM ET
- Accepted
- Feb 2, 5:27 PM ET
- Size
- 13.6 KB